Latest & greatest articles for constipation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on constipation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on constipation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for constipation

81. Consensus Recommendations on Initiating Prescription Therapies for Opioid-Induced Constipation

Consensus Recommendations on Initiating Prescription Therapies for Opioid-Induced Constipation We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Search Results | Pain Medicine | Oxford Academic Search Account Menu Menu Navbar Search Filter Mobile Microsite Search Term Close search filter search input Close mobile search navigation Search Results for Consensus (...) Recommendations on Initiating Prescription Therapies for Opioid-Induced Constipation Modify your search Querybuilder input Citation Year Citation Volume Citation Issue Number Citation Page Filter Abstract All Authors DOI Full Text Keywords References Title Querybuilder input Citation Year Citation Volume Citation Issue Number Citation Page Filter Abstract All Authors DOI Full Text Keywords References Title Querybuilder input Citation Year Citation Volume Citation Issue Number Citation Page Filter Abstract All

2015 American Academy of Pain Medicine

82. Management of Constipation in Adult Patients Receiving Palliative Care

Management of Constipation in Adult Patients Receiving Palliative Care Management of Constipation in Adult Patients Receiving Palliative Care National Clinical Guideline No. 10 November 2015Guideline Development Group The Management of Constipation in Adult Patients Receiving Palliative Care Guideline was developed by a subgroup of the Health Service Executive (HSE)/Royal College of Physicians of Ireland (RCPI) National Clinical Programme for Palliative Care, known as the Guideline Development (...) advice should be sought. This guideline may also be of interest to patients with a life-limiting condition and their carers. This guideline should not be used in patients without a life-limiting illness. This guideline does not apply to children. The National Clinical Guideline and the summary National Clinical Guideline are available on the websites www.health.gov.ie/patient-safety/NCEC and www.hse.ie/palliativecareprogramme. Constipation is one of the most frequently encountered symptoms

2015 National Clinical Guidelines (Ireland)

83. Sacral nerve stimulation for faecal incontinence and constipation: a European consensus statement

Sacral nerve stimulation for faecal incontinence and constipation: a European consensus statement Sacral nerve stimulation for faecal incontinence and constipation: a European consensus statement - Maeda - 2015 - Colorectal Disease - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term Consensus Statement Free Access Sacral nerve stimulation for faecal incontinence and constipation: a European (...) not encountered in the early assessments have been reported - and their management has largely been based on trial and error. There have been many studies on the initial selection criteria for SNS for FI, such as excluding patients with a sphincter defect. The sensitivity of the currently existing assessment procedure, such as the period of peripheral nerve evaluation (PNE), incontinence scores and bowel diaries, has been questioned. There is little information on the long‐term outcome of SNS for constipation

2015 Palliative Care Evidence Review Service (PaCERS)

84. Treatments for Constipation

Treatments for Constipation TITLE: Treatments for Constipation: A Review of Systematic Reviews DATE: 17 November 2014 CONTEXT AND POLICY ISSUES Constipation has many definitions and is often described differently depending on the population queried. Physicians may define constipation as a reduction in the frequency of bowel movements to fewer than three times per week while patients identify more with the symptoms associated with constipation such as difficulty passing stool, hard stool (...) consistency, feelings of abdominal cramping, and feelings of incomplete stool passage. 1 Causes of constipation may be primary (idiopathic) or secondary to other factors such as diet, medication, or medical conditions. 2 Constipation can affect anyone as a minor annoyance but up to a quarter of the population experiences it chronically or severely. 2 It can substantially affect quality of life and be debilitating. 2 It is estimated that between 2% to 27% of the population are affected depending upon

2014 Canadian Agency for Drugs and Technologies in Health - Rapid Review

85. Prucalopride (Resolor) for adult males with chronic constipation ? third line

Prucalopride (Resolor) for adult males with chronic constipation ? third line Prucalopride (Resolor) for adult males with chronic constipation – third line Prucalopride (Resolor) for adult males with chronic constipation – third line NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Prucalopride (Resolor) for adult males (...) with chronic constipation – third line. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Adult; Benzofurans; Chronic Disease; Constipation; Laxatives; Male Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Centre, School of Health&Population Sciences, University of Birmingham, Public

2014 Health Technology Assessment (HTA) Database.

86. Methylnaltrexone bromide (Relistor) for opioid-induced constipation in adult patients with chronic non-malignant pain

Methylnaltrexone bromide (Relistor) for opioid-induced constipation in adult patients with chronic non-malignant pain Methylnaltrexone bromide (Relistor) for opioid-induced constipation in adult patients with chronic non-malignant pain Methylnaltrexone bromide (Relistor) for opioid-induced constipation in adult patients with chronic non-malignant pain NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Methylnaltrexone bromide (Relistor) for opioid-induced constipation in adult patients with chronic non-malignant pain. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Analgesics, Opioid; Constipations; Naltrexone; Narcotic Antagonists Language Published English Country of organisation England English summary

2014 Health Technology Assessment (HTA) Database.

87. Interventions for treating postpartum constipation. (PubMed)

Interventions for treating postpartum constipation. Constipation is a functional bowel disorder that can reduce quality of life in the puerperium period. The diagnosis of postpartum constipation is both subjective and objective. It is characterised by symptoms such as pain or discomfort, straining, hard lumpy stools and a sense of incomplete bowel evacuation. Haemorrhoids, pain at the episiotomy site, effects of pregnancy hormones and hematinics used in pregnancy can increase the risk (...) of postpartum constipation. Although a high fibre diet and increased fluid intake is encouraged to assist defecation in the puerperium, pain-relieving drugs and laxatives are common drugs of choice to alleviate constipation. However, the effectiveness and safety of laxatives on the nursing mother need to be ascertained.To evaluate the effectiveness of interventions for treating postpartum constipation.We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (28 March 2014), the metaRegister

2014 Cochrane

88. Lubiprostone for treating chronic idiopathic constipation

Lubiprostone for treating chronic idiopathic constipation Lubiprostone for treating chronic idiopathic constipation | Guidance | NICE Lubiprostone for treating chronic idiopathic constipation Technology appraisal guidance [TA318] Published date: 23 July 2014 Guidance This guidance has been withdrawn because Takeda has discontinued lubiprostone (Amitiza). Explore © NICE [year]. All rights reserved. Subject to .

2014 National Institute for Health and Clinical Excellence - Technology Appraisals

89. Dioctyl Sulfosuccinate or Docusate (Calcium or Sodium) for the Prevention or Management of Constipation

Dioctyl Sulfosuccinate or Docusate (Calcium or Sodium) for the Prevention or Management of Constipation TITLE: Dioctyl Sulfosuccinate or Docusate (Calcium or Sodium) for the Prevention or Management of Constipation: A Review of the Clinical Effectiveness DATE: 26 June 2014 CONTEXT AND POLICY ISSUES Constipation has many definitions and is often described differently depending on the population queried. Many physicians define constipation as a reduction in the frequency of bowel movements (...) to fewer than three times per week while patients identify more with the symptoms associated with constipation such as difficulty passing stool, hard stool consistency, feelings of abdominal cramping, and feelings of incomplete stool passage. 1 Causes of constipation may be primary (idiopathic) or secondary to other factors such as diet, medication, or medical conditions. 2 Constipation can affect anyone as a minor annoyance but up to a quarter of the population experiences it chronically or severely

2014 Canadian Agency for Drugs and Technologies in Health - Rapid Review

90. Docusate for treatment of constipation

Docusate for treatment of constipation Docusate for treatment of constipation Docusate for treatment of constipation Mitchell MD, Williams K Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Mitchell MD, Williams K. Docusate for treatment of constipation. Philadelphia: Center for Evidence-based Practice (CEP). 2014 Final publication URL Indexing Status Subject (...) indexing assigned by CRD MeSH Constipation; Dioctyl Sulfosuccinic Acids Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence Center for Evidence-based Practice, University of Pennsylvania Health System, 3535 Market St. Suite 50, Philadelphia PA 19104 Email: Cep2@uphs.upenn.edu AccessionNumber 32014000628 Date abstract record published 17/06/2014 Health Technology Assessment (HTA) database Copyright © 2019

2014 Health Technology Assessment (HTA) Database.

91. Biofeedback for treatment of chronic idiopathic constipation in adults. (PubMed)

Biofeedback for treatment of chronic idiopathic constipation in adults. Biofeedback therapy has been used to treat the symptoms of people with chronic constipation referred to specialist services within secondary and tertiary care settings. However, different methods of biofeedback are used within different centres and the magnitude of suggested benefits and comparable effectiveness of different methods of biofeedback has yet to be established.To determine the efficacy and safety of biofeedback (...) for the treatment of chronic idiopathic (functional) constipation in adults.We searched the following databases from inception to 16 December 2013: CENTRAL, the Cochrane Complementary Medicine Field, the Cochrane IBD/FBD Review Group Specialized Register, MEDLINE, EMBASE, CINAHL, British Nursing Index, and PsychINFO. Hand searching of conference proceedings and the reference lists of relevant articles was also undertaken.All randomised trials evaluating biofeedback in adults with chronic idiopathic constipation

Full Text available with Trip Pro

2014 Cochrane

92. Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis

Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis Ford AC, Brenner DM, Schoenfeld PS CRD summary This review found that μ-opioid receptor antagonists were safe and effective (...) for the treatment of opioid-induced constipation. There was some concern over uncertain trial quality but the results appear to be reliable. The conclusion on safety may be overstated given the evidence. Authors' objectives To investigate the evidence for the benefits of pharmacological therapies for opiate-induced constipation. Searching MEDLINE, EMBASE and Cochrane CENTRAL were searched to December 2012 without language restrictions. Search terms were presented. Conference proceedings and reference lists

2014 DARE.

93. Constipation

Constipation TREATMENT OF CONSTIPATION IN PREGNANCY 0344 892 0909 TREATMENT OF CONSTIPATION IN PREGNANCY (Date of issue: March 2018 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Constipation is common in pregnancy and affects (...) approximately 40% of women. It is thought to be caused by progesterone-induced intestinal smooth muscle relaxation. There is very little published epidemiological information available on the potential risks associated with the use of laxatives during pregnancy, however most have minimal systemic absorption and are commonly used during pregnancy without concerns regarding teratogenic effects being raised. Initial treatment of constipation in pregnancy should be non-pharmacological, e.g. exercise, dietary

2014 UK Teratology Information Service

94. Evaluation and Treatment of Functional Constipation in Infants and Children: Evidence-Based Recommendations from ESPGHAN and NASPGHAN

Evaluation and Treatment of Functional Constipation in Infants and Children: Evidence-Based Recommendations from ESPGHAN and NASPGHAN Copyright 2014 by ESPGHAN and NASPGHAN. Unauthorized reproduction of this article is prohibited. Evaluation and Treatment of Functional Constipation in Infants and Children: Evidence-Based Recommendations From ESPGHAN and NASPGHAN M.M. Tabbers, C. DiLorenzo, M.Y. Berger, C. Faure, M.W. Langendam, S. Nurko, A. Staiano, Y. Vandenplas, and M.A. Benninga ABSTRACT (...) Background:Constipationisapediatricproblemcommonlyencounteredby many health care workers in primary, secondary, and tertiary care. To assist medical care providers in the evaluation and management of children with functional constipation, the North American Society for Pediatric Gastro- enterology,Hepatology,andNutritionandtheEuropeanSocietyforPediatric Gastroenterology, Hepatology, and Nutrition were charged with the task of developing a uniform document of evidence-based guidelines. Methods: Nine clinical questions addressing diagnostic, therapeutic

2014 North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition

95. The role of endoscopy in the management of constipation

The role of endoscopy in the management of constipation GUIDELINE The role of endoscopy in the management of constipation This is one of a series of statements discussing the use of GI endoscopy in common clinical situations. The Stan- dards of Practice Committee of the American Society for Gastrointestinal Endoscopy (ASGE) prepared this guideline. Inpreparingthisdocument,MEDLINEdatabaseswereused to search for publications pertaining to this topic between January 1990 and December 2013 (...) of thepatient’scondition and available coursesof action. Therefore,clinical considerations mayleadan endoscop- ist to take a course of action that varies from the recom- mendations and suggestions proposed in this document. INTRODUCTION AND EPIDEMIOLOGY Constipation is a common symptom affecting 2% to 27% of the population and resulting in about 2.5 million physician visits in the United States annually. 2,3 The preva- lence of constipation is higher in women than in men 4 and increases with age. 5 Low socioeconomic

2014 American Society for Gastrointestinal Endoscopy

96. Movantik (naloxegol) - To treat opioid-induced constipation in adults with chronic non-cancer pain

Movantik (naloxegol) - To treat opioid-induced constipation in adults with chronic non-cancer pain Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - MOVANTIK (naloxegol) Tablets Company: AstraZeneca Pharmaceuticals LP Application No.: 204760 Approval Date: 9/16/2014 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF

2014 FDA - Drug Approval Package

97. Treatments for constipation: a review of systematic reviews

Treatments for constipation: a review of systematic reviews Treatments for constipation: a review of systematic reviews Treatments for constipation: a review of systematic reviews CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Treatments for constipation: a review of systematic reviews. Ottawa: Canadian Agency for Drugs (...) and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions In adults and children with chronic constipation, polyethylene glycol (PEG), increased the frequency of stools relative to placebo, lactulose and milk of magnesia. Stool frequency was also increased in adults treated with prucalopride versus placebo. Laxatives and prucalopride may increase the risk of diarrhea. No conclusions can be drawn with regards to stool softeners or bulking agents. The available studies were generally of lower

2014 Health Technology Assessment (HTA) Database.

98. Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain. (PubMed)

Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain. Opioid-induced constipation is common and debilitating. We investigated the efficacy and safety of naloxegol, an oral, peripherally acting, μ-opioid receptor antagonist, for the treatment of opioid-induced constipation.In two identical phase 3, double-blind studies (study 04, 652 participants; study 05, 700 participants), outpatients with noncancer pain and opioid-induced constipation were randomly assigned to receive

2014 NEJM

99. Dioctyl sulfosuccinate or docusate (calcium or sodium) for the prevention or management of constipation: a review of the clinical effectiveness

Dioctyl sulfosuccinate or docusate (calcium or sodium) for the prevention or management of constipation: a review of the clinical effectiveness Dioctyl sulfosuccinate or docusate (calcium or sodium) for the prevention or management of constipation: a review of the clinical effectiveness Dioctyl sulfosuccinate or docusate (calcium or sodium) for the prevention or management of constipation: a review of the clinical effectiveness CADTH Record Status This is a bibliographic record of a published (...) health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Dioctyl sulfosuccinate or docusate (calcium or sodium) for the prevention or management of constipation: a review of the clinical effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions There remains a paucity of good quality evidence to support the use of docusate

2014 Health Technology Assessment (HTA) Database.

100. Management of faecal incontinence and constipation in adults with central neurological diseases. (PubMed)

Management of faecal incontinence and constipation in adults with central neurological diseases. People with central neurological disease or injury have a much higher risk of both faecal incontinence and constipation than the general population. There is often a fine line between the two symptoms, with any management intended to ameliorate one risking precipitating the other. Bowel problems are observed to be the cause of much anxiety and may reduce quality of life in these people. Current (...) strategies for faecal incontinence and constipation in people with a neurological disease or injury affecting the central nervous system.We searched the Cochrane Incontinence Group Trials Register (searched 8 June 2012), which includes searches of the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and MEDLINE In-Process as well as handsearching of journals and conference proceedings; and all reference lists of relevant articles.Randomised and quasi-randomised trials evaluating any type

Full Text available with Trip Pro

2013 Cochrane